Comparative Pharmacology
Head-to-head clinical analysis: AZOR versus HYDRAP ES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZOR versus HYDRAP ES.
AZOR vs HYDRAP-ES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amlodipine is a dihydropyridine calcium channel blocker that inhibits calcium ion influx across cardiac and vascular smooth muscle cells, causing vasodilation and reduced peripheral vascular resistance. Olmesartan is an angiotensin II receptor blocker (ARB) that selectively blocks AT1 receptors, inhibiting vasoconstriction and aldosterone secretion.
Hydralazine is a direct-acting vasodilator that relaxes arteriolar smooth muscle, leading to decreased systemic vascular resistance and reduced blood pressure. The exact molecular mechanism involves inhibition of inositol trisphosphate (IP3)-induced calcium release from the sarcoplasmic reticulum and activation of guanylate cyclase, increasing cGMP levels.
AZOR is a combination of amlodipine and olmesartan. Typical adult dose: one tablet orally once daily. Available strengths: amlodipine/olmesartan 5mg/20mg, 5mg/40mg, 10mg/20mg, 10mg/40mg. Dose can be titrated based on blood pressure response.
Oral: 25-50 mg twice daily, max 200 mg/day. IV: 10-20 mg every 4-6 hours as needed.
None Documented
None Documented
Amlodipine: 30-50 h (terminal); supports once-daily dosing. Olmesartan: 10-15 h (terminal); once-daily dosing effective
Terminal elimination half-life is 2-4 hours in patients with normal renal function; prolonged in renal impairment (up to 20 hours in severe cases).
Renal: 90% (amlodipine: 60% as metabolites, 10% as parent; olmesartan: 35-50% as parent via urine, rest in feces via bile). Fecal: 10%
Primarily renal (80-90% as unchanged drug); minor biliary/fecal (<10%).
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination